Browse Category

NYSE:LLY 28 February 2026 - 6 June 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Eli Lilly Stock Sets High Ahead of Monday Data

Eli Lilly shares finished the week at a record high close, gaining 0.6% Friday at $1,131.42. On Saturday, the company put out late-stage results showing its retatrutide injection, still experimental, cut obstructive sleep apnea severity by 60.6% and reduced knee osteoarthritis pain by as much as 73.1% in obese adults.

6 June 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics AG shares surged in early afternoon U.S. trade Thursday, up 11.7% at $58.15. Investors moved into gene-editing stocks. The Nasdaq name hit an intraday high of $59.00. About 2.0 million shares traded, putting its market cap close to $5.6 billion.

4 June 2026

Biotechnology·NASDAQ:BEAM·NASDAQ:CRSP·NASDAQ:EDIT·NASDAQ:NTLA·NASDAQ:VRTX·NYSE:LLY·Stock Market

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Eli Lilly & Co. is picking up Curevo Inc., LimmaTech Biologics AG and Vaccine Company Inc. in three cash acquisitions worth as much as $3.83 billion. With the deals, the U.S. drugmaker gets its hands on vaccine programs for shingles, staph infections and Epstein-Barr virus.

28 May 2026

NASDAQ:CNTX·NYSE:GSK·NYSE:LLY·Pharmaceuticals

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Investors eye Hims & Hers Health Inc. as it approaches Monday’s first-quarter results, with attention locked on the future of its weight-loss segment—especially after the company pulled back from widely promoted compounded GLP-1 drugs. Earnings will post after the U.S. markets close, followed by a 5 p.m. ET conference call, according to Hims & Hers.

11 May 2026

Earnings·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk bumped up its 2026 forecast on Wednesday, buoyed by stronger-than-expected initial sales for its Wegovy weight-loss pill—a fresh win in its rivalry with Eli Lilly. In Copenhagen, the stock jumped up to 9.2% after Novo told investors it now expects this year’s drops in sales and profit to be less steep than it previously warned.

6 May 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Shares of Cabaletta Bio Inc. surged roughly 32% late Monday, buoyed by news of early results from a small cell-therapy trial and the announcement of a $150 million stock sale that counted Eli Lilly among its participants. Trading hit $3.895 on strong volume, topping out intraday at $4.04, according to market data.

4 May 2026

Biotechnology·Healthcare Innovation·NASDAQ:CABA·NYSE:LLY·Stock Market

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly hiked its full-year outlook for both sales and profit Thursday, following a jump in quarterly revenue driven by strong uptake of its diabetes drug Mounjaro and obesity therapy Zepbound. First-quarter revenue climbed 56% to $19.8 billion, according to the Indianapolis-based company, with adjusted earnings coming in at $8.55 per share.

30 April 2026

Financial Forecasts·NYSE:LLY·Pharmaceuticals

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Prescriptions for Eli Lilly and Company’s new oral weight-loss drug Foundayo reached 3,707 in the U.S. during its second week, according to IQVIA data cited by analysts. That’s behind the early numbers seen for Novo Nordisk’s competing Wegovy pill and has weighed on Lilly shares. In its launch week, Foundayo saw 1,390 prescriptions.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk A/S’s Wegovy pill stayed ahead in the early going, with 18,410 U.S. prescriptions at the same stage of launch where Eli Lilly’s Foundayo managed 3,707 in its second week, according to analysts referencing IQVIA data. RBC Capital Markets analyst Trung Huynh flagged that it’s early days and comparisons can be tricky, but noted that Foundayo’s latest numbers are likely to be viewed as a disappointment.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health announced Thursday that its providers are now able to send prescriptions for Eli Lilly’s Zepbound vials, the Zepbound KwikPen, and the Foundayo pill directly to LillyDirect. With this move, the telehealth company is expanding its reach into branded obesity treatments. The company said that, combined with its previous Novo Nordisk partnership, it now offers what it describes as the full lineup of FDA-approved GLP-1 drugs on its platform.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health dropped 1.6% to $30.52 in afternoon trading Tuesday, sliding after Amazon rolled out a GLP-1 weight-management program via One Medical. Shares, which opened at $28.31 and touched a session low of $28.01, took a hit as the telehealth firm faces increased heat to revamp its weight-loss segment.

21 April 2026

NASDAQ:AMZN·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly on Monday agreed to buy Boston’s Kelonia Therapeutics in a deal valued at up to $7 billion in cash, adding a fresh in vivo cell therapy play to its pipeline. The drugmaker will pay $3.25 billion upfront, with the balance subject to hitting clinical, regulatory, and commercial milestones.

21 April 2026

Biotechnology·NYSE:LLY·Pharmaceuticals

Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly agreed to acquire Boston-based Kelonia Therapeutics for up to $7 billion on Monday, handing the drugmaker a new bet on experimental cell therapies for blood cancer as it keeps widening its pipeline beyond weight-loss medicines. Lilly shares were up about 2.5% in morning trading.

20 April 2026

Healthcare Innovation·NYSE:LLY

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly kicks off the week with a fresh pipeline pact in hand. Insilico Medicine on Sunday announced it struck a global licensing and research deal with the U.S. pharma giant, a tie-up valued at as much as $2.75 billion. Lilly shares finished Friday at $878.24, off 2.1%. The stock sits more than 22% beneath its Jan. 8 peak.

29 March 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly shares grabbed attention Thursday, with the drugmaker reporting its experimental obesity and diabetes therapy, retatrutide, hit the primary endpoint in a late-stage trial—showing notable drops in both weight and blood sugar. The stock last changed hands at $918.05, off 1.3% early, after Tuesday’s nearly 6% tumble that followed a rare downgrade from HSBC.

19 March 2026

Health News·NYSE:LLY·Pharmaceuticals·Stock Market

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket action as of 9:00 a.m. EDT on Thursday, following a 10.3% jump to $25.88 at Wednesday’s close. That put the telehealth company on track for its fourth consecutive advance.

12 March 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said on Monday its experimental obesity drug ABBV-295 helped adults lose up to 9.79% of their body weight in 12 weeks in an early-stage study, giving the drugmaker its clearest sign yet that it may have a contender in a market led by Eli Lilly and Novo Nordisk. The company said no serious adverse events were reported.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly and Company wrapped up Tuesday’s session down roughly 1%, settling at $1,007.73. That followed a 3.23% drop the previous day.

4 March 2026

NASDAQ:VTYX·NYSE:LLY·Pharmaceuticals·Stock Market

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly and Company shares slipped 2.3% to $1,028.07 in Monday afternoon trading. Earlier in the session, the stock climbed as high as $1,056.84 but also dropped to $1,023.50 at its lowest. The drugmaker now holds a market value near $686 billion.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

Eli Lilly and Co jumped 2.93% to finish at $1,051.99 on Friday, breaking a three-session slide. U.S. markets remain closed Saturday.

28 February 2026

NYSE:LLY·Stock Market

Previous 1 2 3 4 … 14 Next

NYSE:LLY 28 February 2026 - 6 June 2026

Eli Lilly Stock Sets High Ahead of Monday Data

CRISPR Therapeutics Jumps 12% in New York Trading

Eli Lilly’s $20 Billion M&A Push Moves Into Vaccines

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy

Eli Lilly Raises 2026 Forecast as Mounjaro, Zepbound Sales Keep Weight-Loss Boom Alive

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Eli Lilly to Buy Kelonia for Up to $7 Billion as In Vivo CAR-T Gains Ground

Eli Lilly to Buy Kelonia for Up to $7 Billion in Bet on Next-Gen CAR-T Cancer Therapy

Eli Lilly and Company Stock Price: LLY Closes at $878.24 as Insilico Deal, Trial Data Put Monday in Focus

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

Eli Lilly stock slips again as April orforglipron decision and FDA GLP-1 ad crackdown loom

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly stock price rebounds above $1,050 — what traders are watching next

TechStock² Updates

QSR Stock Awaits Market Response as Tim Hortons Launches Harry Potter Menu After Flat Sales

Shake Shack Shares Steady Despite Viral Kiosk Glitch Impacting Licensed Locations

Mondelez Shares (MDLZ) Tick Up Amid Oreo Momentum in China Highlighting Higher Volumes

Beyond Meat Stock Slides 20% as BYND’s 1-for-30 Split Starts a 12-Session Nasdaq Test

Nebius Shares Rise 5% on NASDAQ, $2 Billion Revenue Target Sets Challenge for H2 Earnings

Top Stock Picks

Taiwan Semiconductor

AerCap

Constellation Energy

Walt Disney

American International Group

Live updates

Investment Disclaimer